Fierce PharmaMarketing
| By Beth Snyder Bulik
Pfizer ($PFE) owned TV ad spending for 2015 among pharma brands. It took 5 spots on the top 10 list for the year, including Nos. 1 and 2, according to iSpot.tv estimated spending tallied for FiercePharmaMarketing. Seizure and pain drug Lyrica came in first with $116.2 million spent in 2015, while Pfizer's pneumococcal pneumonia vaccine Prevnar 13 came in at No. 2 with $101.7 million.
Pfizer ($PFE) owned TV ad spending for 2015 among pharma brands. It took 5 spots on the top 10 list for the year, including Nos. 1 and 2, according to iSpot.tv estimated spending tallied for FiercePharmaMarketing. Seizure and pain drug Lyrica came in first with $116.2 million spent in 2015, while Pfizer's pneumococcal pneumonia vaccine Prevnar 13 came in at No. 2 with $101.7 million.
The three other Pfizer drugs on the list were
anticoagulant Eliquis (No. 5), arthritis fighter Xeljanz (No. 6) and smoking
cessation drug Chantix (No. 9), spending $96.7 million, $85.3 million, and
$68.5 million respectively, according to iSpot.tv data.
Other Big Pharmas divvied up the remaining
spots. Johnson & Johnson's ($JNJ) diabetes drug Invokana was No. 3 at
$101.3 million, while AbbVie's ($ABBV) Humira was No. 4. One unfortunate note
at No. 10 was Sanofi's ($SNY) epinephrine product Auvi-Q, which spent $54.2
million in TV advertising, only to have to pull all its injectors on worries
that they might be delivering incorrect dosages.